Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05002569 |
| Consolidated Lead Sponsor | Bristol Myers Squibb |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 1,093 participants (ACTUAL) |
| Registered Start Date | 2021-10-19 |
| WhyStopped Classification | Unspecified |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Moffitt Cancer Center | Tampa, FL | Open Hospital Dossier -> |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City, IA | Open Hospital Dossier -> |
| Dana-Farber Cancer Institute | Boston, MA | Open Hospital Dossier -> |
| Mount Sinai Hospital and Icahn School of Medicine | New York, NY | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.